Effectiveness of Switch to Erythropoiesis-Stimulating Agent (ESA) Biosimilars versus Maintenance of ESA Originators in the Real-Life Setting: Matched-Control Study in Hemodialysis Patients
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Drug Investigation"
DOI: 10.1007/s40261-017-0562-8
Abstract: BackgroundIn hemodialysis (HD), switching from erythropoiesis-stimulating agent (ESA) originators to biosimilars is associated with the need for doses approximately 10% higher, according to industry-driven studies.ObjectiveThe aim of this study was to evaluate the efficacy on… read more here.
Keywords: esa originators; control; switch; study ... See more keywords